elbasvir; grazoprevir - Profile

What are the generic drug sources for elbasvir; grazoprevir and what is the scope of freedom to operate?

Elbasvir; grazoprevir is the generic ingredient in one branded drug marketed by Msd Sub Merck and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Summary for elbasvir; grazoprevir

International Patents:	114
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for elbasvir; grazoprevir

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for elbasvir; grazoprevir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	ZEPATIER	elbasvir; grazoprevir	TABLET;ORAL	208261-001	Jan 28, 2016		DISCN	Yes	No			Y	Y
Msd Sub Merck	ZEPATIER	elbasvir; grazoprevir	TABLET;ORAL	208261-001	Jan 28, 2016		DISCN	Yes	No			Y	Y

EU/EMA Drug Approvals for elbasvir; grazoprevir

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Zepatier	elbasvir, grazoprevir	EMEA/H/C/004126ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1.	Authorised	no	no	no	2016-07-22

International Patents for elbasvir; grazoprevir

Country	Patent Number	Title	Estimated Expiration
Argentina	072588
Australia	2009274190
Brazil	PI0916235
Canada	2731177
Chile	2011000145
China	102159285

Supplementary Protection Certificates for elbasvir; grazoprevir

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2310095	1690068-0	Sweden		PRODUCT NAME: GRAZOPREVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/16/1119 20160726
2410844	LUC00003	Luxembourg		PRODUCT NAME: ELBASVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI / ZEPATIER - ELBASVIR/GRAZOPREVIR; AUTHORISATION NUMBER AND DATE: EU/1/16/1119
2310095	2/2017	Austria		PRODUCT NAME: GRAZOPREVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1119 (MITTEILUNG) 20160726
2310095	132017000002002	Italy		PRODUCT NAME: GRAZOPREVIR O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ZEPATIER); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1119, 20160726
2310095	201640058	Slovenia		PRODUCT NAME: GRAZOPREVIR; NATIONAL AUTHORISATION NUMBER: EU/1/16/1119; DATE OF NATIONAL AUTHORISATION: 20160722; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2310095	PA2016049,C2310095	Lithuania		PRODUCT NAME: GRAZOPREVIRAS ARBA FARMACISKAI PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/16/1119 20160722

Investment Scenario, Market Dynamics, and Financial Trajectory of Elbasvir and Grazoprevir

Last updated: February 3, 2026

Executive Summary

Elbasvir and Grazoprevir constitute a combination antiviral therapy approved for treating hepatitis C virus (HCV) infections, specifically genotypes 1 and 4. Marketed primarily under the brand name Zepatier, these drugs have experienced variable commercial performance due to competition from direct-acting antivirals (DAAs). This report analyzes the current market landscape, investment outlook, and projected financial trajectory for Elbasvir and Grazoprevir, considering recent developments, patent status, competitive positioning, and market trends.

---

1. Product Overview and Commercial Status

Attribute	Details
Active Ingredients	Elbasvir (NS5A inhibitor), Grazoprevir (NS3/4A protease inhibitor)
Indications	Chronic HCV genotypes 1 and 4
Approval Date (FDA)	January 2016
Regulatory Bodies	FDA, EMA, other national agencies
Marketed by	Merck & Co. (MSD)

Key Highlights:

• Zepatier's first approval marked a significant advance in pan-genotypic HCV treatment.
• The treatment's efficacy: >95% sustained virologic response (SVR) in clinical trials.
• Price point: Approximate wholesale price (AWP) of $54,300 for a 12-week course, positioning as a mid-tier agent.

---

2. Market Dynamics

2.1. Competitive Landscape

Competitor Drugs	Mechanism	Market Entry Year	Market Share (2022)	Notes
Epclusa (Sofosbuvir/Velpatasvir)	Pan-genotypic NS5B and NS5A inhibitor	2016	~25%	Broad genotype coverage
Mavyret (Glecaprevir/Pibrentasvir)	Pan-genotypic NS3/4A protease/NS5A inhibitor	2017	~30%	Shorter treatment courses
Harvoni (Ledipasvir/Sofosbuvir)	Genotype 1-4	2014	Declining	High efficacy but higher cost

Market Trend:

• Increasing preference for pan-genotypic regimens simplifies treatment algorithms.
• High cure rates reduce new patient pool, impacting revenue.
• Price competition has been intense, with some generics available in emerging markets.

2.2. Patent and Exclusivity Status

Patent	Expiry Year	Status	Comments
Primary composition patent	2028	Active	Potential for generic competition post-expiry
Method of use patents	2030	Active	May extend commercial exclusivity

Implications:

• Limited patent life poses a competitive threat post-2028.
• Patent cliffs could lead to price erosion and volume-based competition.

2.3. Market Penetration Strategies

• Pricing and Reimbursement: Negotiations with healthcare payers influence accessibility.
• Combination Therapies: Developing fixed-dose combinations to improve adherence.
• Global Expansion: Targeting emerging markets with lower-cost generics.

2.4. Regulatory and Policy Impact

• Pricing Regulations: US and European agencies favor cost-effective treatments.
• Guideline Updates: Favor regimens with higher efficacy, influencing market share.

---

3. Financial Trajectory and Investment Outlook

3.1. Revenue Forecast (2023-2030)

Year	Estimated Global Revenue (USD million)	Assumptions
2023	150	Post-pandemic recovery, moderate adoption
2024	130	Market share slight decline due to competition
2025	110	Patent expirations approaching, generic impact
2026	80	Significant price erosion expected
2027	50	Market saturation, competition prevails
2028	20	Patent expiry; generic versions impact revenue
2029-2030	<10	Residual sales, niche markets

Note: The decline is analogous to trends observed for other HCV therapies, with a sharp drop post-patent expiry.

3.2. Cost Structure and Profit Margins

Component	% of Total Cost	Details
R&D	10-15%	Largely amortized; minimal ongoing R&D budgets
Manufacturing	20%	Scale-dependent; patent protection maintains margins
Marketing & Sales	25%	Major expense, influenced by market penetration strategies
Regulatory & Legal	5%	Includes patent defense and compliance

Profitability Outlook:

• Short-term profitability stable; long-term margins threatened by generic competition.

3.3. Investment Opportunities

• Licensing and Partnerships: Opportunities for licensing deals targeting emerging markets.
• Generic Production: Entry into generics could provide revenue streams post-patent.
• Pipeline Expansion: Potential benefit from combination therapies extending product lifecycle.

---

4. Market and Financial Comparison with Competitors

Aspect	Elbasvir/Grazoprevir (Zepatier)	Epclusa	Mavyret	Harvoni
Market Launch Year	2016	2016	2017	2014
Regulatory approvals	FDA, EMA	FDA, EMA	FDA, EMA	FDA, EMA
Price per 12-week	~$54,300	~$74,760	~$26,400	~$94,500
SVR Rate	>95%	>95%	>95%	>95%
Patent expiry	Approx. 2028	2026	2026	2023 for some components

Note: The lower price point makes Mavyret attractive in price-sensitive markets, while higher-cost treatments maintain higher margins.

---

5. Key Market Trends and Future Outlook

5.1. Generics and Price Erosion

Post-2028 patent expiration expects a marked decrease in revenue. Generic manufacturers are likely to reduce prices substantially—by 60-80%—mirroring observed patterns in similar pharmaceuticals.

5.2. Market Demand Dynamics

• Decline in new diagnoses: Due to high cure rates, the prevalence diminishes.
• Treatment simplification: Fewer regimens preferred, reducing therapy diversity.
• Global health initiatives: Increased access in low-income countries can create new markets.

5.3. Innovation and Pipeline Developments

• Focus on pan-genotypic, shorter, and safer regimens.
• Potential combination with other antiviral agents to expand indications.
• No current indications for pediatric or special populations, limiting growth.

---

6. SWOT Analysis

Strengths	Weaknesses	Opportunities	Threats
Efficacious with high SVR	Limited genotype coverage	Expanding in emerging markets	Patent expiry leading to generic entry
Established regulatory approval	Moderate market share	Development of fixed-dose combinations	Competitive landscape with more affordable options
Strong manufacturing	Price point	Pipeline development	Regulatory and reimbursement hurdles

---

7. Conclusion

Elbasvir and Grazoprevir's commercial outlook is primarily influenced by patent expiration, competitive offerings, and evolving treatment guidelines. Investment focus should shift from revenue growth to strategic licensing, pipeline innovation, and market expansion before patent expiry. The combined product displays strong efficacy but faces imminent generic competition, necessitating proactive positioning.

---

Key Takeaways

• Market position: Currently substantial in genotype-specific HCV treatment, but poised for decline post-2028.
• Revenue trajectory: Expected to decline sharply after patent expiration, with residual niche sales.
• Competitive threats: Generic entrants and price erosion will dominate the post-patent landscape.
• Investment focus: Opportunities in licensing, emerging markets, and pipeline development.
• Strategic recommendation: Diversify beyond current formulations; monitor patent status and competitor moves.

---

FAQs

Q1: When is the patent for Elbasvir and Grazoprevir expected to expire?
Answer: Approximate patent expiry is in 2028, though this can vary depending on jurisdiction and any patent extensions.

Q2: How does the efficacy of Zepatier compare with other HCV treatments?
Answer: It demonstrates SVR rates exceeding 95%, comparable to other leading DAAs like Epclusa and Mavyret.

Q3: What market segments are most lucrative for Elbasvir and Grazoprevir?
Answer: Currently, developed markets; post-patent expiry, emerging markets with lower pricing will be critical.

Q4: Are there any ongoing pipeline developments for Elbasvir and Grazoprevir?
Answer: No significant pipeline expansions; the focus remains on optimizing current formulations and combination therapies.

Q5: What factors could extend the commercial life of these drugs?
Answer: Development of new indications, fixed-dose combinations, or formulation improvements could extend lifecycle, but patent protection dominates market potential.

---

References

1. FDA Drug Approvals: U.S. Food and Drug Administration. Zepatier (Elbasvir and Grazoprevir). January 2016.
2. Market Data: IQVIA. Global Hepatitis C Market Report (2022).
3. Patent Status: PharmaPatents.com. Elbasvir/Grazoprevir patent timelines.
4. Competitive Analysis: EvaluatePharma. HCV Drug Market Landscape, 2022.
5. Regulatory Insights: EMA & FDA. HCV Treatment Guidelines and Approvals.